[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.65.227. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 26, 1948

ORAL "MYANESIN" IN TREATMENT OF SPASTIC AND HYPERKINETIC DISORDERS

Author Affiliations

Rochester, N. Y.

From the Department of Pediatrics and Division of Orthopedics, the University of Rochester School of Medicine and Dentistry.

JAMA. 1948;137(9):772-774. doi:10.1001/jama.1948.02890430014004
Abstract

The interesting pharmacologic properties of " myanesin" (3-ortho-toloxy-1,2-propanediol), such as its power to relax spasticity and rigidity, its action to restore deranged reciprocal innervation and its inhibiting effect on certain release symptoms, suggested that this drug may be useful in the production of muscular relaxation during anesthesia and for the treatment of certain spastic and hyperkinetic disorders. "Myanesin" has since been widely used for muscle relaxation during anesthesia in Great Britain, and it was recently reported that 10,000 patients received intravenous injections of this agent.3

The value of "myanesin" in the treatment of spastic and hyperkinetic disorders has not been examined as extensively. Stephen and Chandy4 obtained short-lived beneficial effects on certain diseases of the extrapyramidal nervous system on intravenous administration of a 10 per cent solution of the drug. They also observed localized thrombophlebitis and transient hemoglobinuria following administration. These side effects were due to the solvents used

First Page Preview View Large
First page PDF preview
First page PDF preview
×